drugset / Trial / NCT00753324
Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia
Phase 4
Completed
284 enrolled
University of North Carolina, Chapel Hill
Doris Duke Charitable Foundation · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The investigators will enroll a cohort of HIV-infected pregnant women accessing PMTCT services, to better understand the incremental benefits (e.g. reduction in HIV transmission, improvements in HIV-free survival) and risks (e.g. drug toxicities) of the routine HAART strategy, in comparison to HIV-infected pregnant women accessing the Zambian Standard of Care services. The investigators will test the hypothesis that routine use of HAART produces significant reductions in HIV transmission rates, with only minimal side effects.
Timeline
- Start
- 2009-05
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lamivudine | Other / unclassified | — | — |
| Subject | Lopinavir | Other / unclassified | — | — |
| Subject | Nevirapine | Small molecule | — | — |
| Subject | Ritonavir | Other / unclassified | — | — |
| Subject | Stavudine | Other / unclassified | — | — |
| Subject | Zidovudine | Small molecule | — | — |